IASLC tumor budding grade identifies high-risk patients with resected lung squamous cell carcinoma
A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding–based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer (WCLC).
A new grading system proposed by the International Association for the Study of Lung Cancer (IASLC) has been shown to successfully identify high-risk patients with resected lung squamous cell carcinoma (SqCC) at the 2026 World Conference on Lung Cancer. The study, conducted at Yonsei University Medical Center in Seoul, Republic of Korea, retrospectively reviewed 585 patients who underwent curative-intent upfront resection between 2015 and 2022.
The research found that the IASLC tumor budding-based grading system, which classifies resected lung SqCC as low or high grade based solely on tumor budding, could identify patients with poorer prognosis and suggest that high-grade patients may benefit most from adjuvant chemotherapy. The findings were independently validated, showing that high-grade tumors were associated with worse overall and disease-free survival, while low-grade tumors showed no benefit from adjuvant chemotherapy.
Prospective multicenter validation is needed to confirm the potential role of this grading system in treatment selection.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
